Evidence map›Paper›PMID 35133032›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2022

TCF7L2 transcriptionally regulates Fgf15 to maintain bile acid and lipid homeostasis through gut-liver crosstalk.

Neha Bhat, Fatemehsadat Esteghamat, Bal Krishna Chaube, Kushan Gunawardhana, Mitra Mani, Clay Thames, Dhanpat Jain, Henry N Ginsberg, Carlos Fernandes-Hernando, Arya Mani

Erratum issuedOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Neha BhatDepartment of Internal Medicine, Cardiovascular Research Center, Yale University School of Medicine, New Haven, Connecticut, USA.
Fatemehsadat EsteghamatDepartment of Internal Medicine, Cardiovascular Research Center, Yale University School of Medicine, New Haven, Connecticut, USA.
Bal Krishna ChaubeDepartment of Comparative Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
Kushan GunawardhanaDepartment of Internal Medicine, Cardiovascular Research Center, Yale University School of Medicine, New Haven, Connecticut, USA.
Mitra ManiNew York Medical College, Valhalla, New York, USA.
Clay ThamesDepartment of Internal Medicine, Cardiovascular Research Center, Yale University School of Medicine, New Haven, Connecticut, USA.
Dhanpat JainDepartment of Pathology, Yale School of Medicine, New Haven, Connecticut, USA.
Henry N GinsbergDepartment of Internal Medicine, Columbia University College of Physicians and Surgeon, New York, New York, USA.
Carlos Fernandes-HernandoDepartment of Comparative Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
Arya ManiDepartment of Internal Medicine, Cardiovascular Research Center, Yale University School of Medicine, New Haven, Connecticut, USA.
Yale University · USColumbia University · US

Funding

The Identification and characterization of genetic variants underlying cardiovascular diseasesR35HL135767 · NHLBI · YALE UNIVERSITY · PI MANI, ARYA · 2017 to 2023
$7.0M
Phenotyping Genetic Disorders of Hepatic Lipid and Lipoprotein Metabolism in Cells, Mice, and MenR35HL135833 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2017 to 2023
$6.7M
NHLBI NIH HHS R35 HL135767NHLBI NIH HHS R35 HL135833
6 · The paper itself

Abstract

FGF19/FGF15 is an endocrine regulator of hepatic bile salt and lipid metabolism, which has shown promising effects in the treatment of NASH in clinical trials. FGF19/15 is transcribed and released from enterocytes of the small intestine into enterohepatic circulation in response to bile-induced FXR activation. Previously, the TSS of FGF19 was identified to bind Wnt-regulated TCF7L2/encoded transcription factor TCF4 in colorectal cancer cells. Impaired Wnt signaling and specifical loss of function of its coreceptor LRP6 have been associated with NASH. We, therefore, examined if TCF7L2/TCF4 upregulates Fgf19 in the small intestine and restrains NASH through gut-liver crosstalk. We examined the mice globally overexpressing, haploinsufficient, and conditional knockout models of TCF7L2 in the intestinal epithelium. The TCF7L2

Indexed as

Lipid MetabolismAnimalsBile Acids and SaltsCholesterol 7-alpha-HydroxylaseFibroblast Growth FactorsHomeostasisIleumLiverLow Density Lipoprotein Receptor-Related Protein-6MiceMice, Inbred C57BLNon-alcoholic Fatty Liver DiseaseTranscription Factor 7-Like 2 ProteinBile Acids and SaltsCholesterol 7-alpha-HydroxylaseCyp7a1 protein, mousefibroblast growth factor 15, mouseFibroblast Growth FactorsLow Density Lipoprotein Receptor-Related Protein-6Lrp6 protein, mouseTcf7l2 protein, mouseTranscription Factor 7-Like 2 ProteinFgf19lipid absorptionNASHtcf7l2

Identifiers

PMID35133032
PMCPMC9624374
OpenAlexW4210832660

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.